UCB - Current Assets


UCB reported EUR6.05B in Current Assets for its fiscal semester ending in December of 2025.





Current Assets Change Date
Alcon AG USD 6.62B 4M Jun/2026
Almirall EUR 747.1M 33.12M Jun/2026
Amarin USD 612.88M 10.12M Sep/2026
argenx SE USD 8.07B 1.17B Jun/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Bayer EUR 39.6B 5.96B Sep/2026
Genmab DKK 2.8B 228M Jun/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
GRIFOLS EUR 5.35B 40M Sep/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Lakefront Biotherapeutics EUR 2.31B 751.38M Jun/2026
Lonza CHF 8B 3.41B Dec/2025
Merck EUR 15.14B 1.37B Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Orion EUR 1.34B 139.5M Sep/2026
Recordati EUR 1.89B 128.35M Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 33.21B 1.68B Sep/2026
UCB EUR 6.05B 733M Dec/2025
Unibail Rodamco EUR 3.97B 1.09B Dec/2025